Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. - Wikidata - wikimedia - TriplyDB

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

http://www.wikidata.org/entity/Q36460314

about

Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer Adoptive cell therapy for sarcoma Improving natural killer cell cancer immunotherapy NK cells in therapy of cancer CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Present and Future of Allogeneic Natural Killer Cell Therapy The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.Combination immune therapies to enhance anti-tumor responses by NK cells.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer.Role of Natural Killer Cells in HIV-Associated Malignancies.Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.The tumor microenvironment: a pitch for multiple players.Clinical utility of natural killer cells in cancer therapy and transplantation.The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment."NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker The antileukemic potential of natural killer cells.Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia.Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection Emerging biological therapies to treat acute lymphoblastic leukemia.Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.A novel bispecific antibody, BiSS, with potent anti-cancer activities.One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells.IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.

P2860

Q26751011-D3CDC6D6-3B7F-49BE-9CF4-A8CC0B95CE90 Q26771449-E4C9213D-0C51-4DD8-852F-7D4774DC52F3 Q26773135-D08FACC0-26FA-4193-9E70-7D51C7C687C1 Q26797345-C0DFB7F3-8E7F-4B17-AAEF-3F51C6B6EFA7 Q26853171-A185195D-D1F0-45E7-A66A-82C63A7C6D60 Q27009541-83D31FD2-49CA-48C3-87BE-69711FCAA223 Q28087719-BA2C0982-D158-4556-879F-E06052EC25D9 Q28242241-A72E7CF1-4195-4B42-B1D1-C2675A8DEEF6 Q33585293-EB2E1848-B06F-40E3-9A58-BE54DD0A26DF Q33770125-530D621E-704E-4A9E-A68B-510ED2A3430A Q34550963-C2BE1610-F4D1-4F37-B53F-342A04BE9E51 Q35600095-7E704DA1-4592-4CEC-9220-2B9870507EB7 Q35677351-B7B5B8A6-07AF-4BF5-9C0F-B5A56690F1CB Q36772346-B80C3185-C637-4B98-B4D6-F065FBE70B32 Q37376659-816A848A-57DD-448C-9F96-C10CB8C43EAE Q37408550-EC1EFB26-AA54-4285-95DE-58AFD9B32CA2 Q37579561-BAD6450F-649E-4536-A7C4-EF84BCEEA938 Q37589671-C019742A-4F95-454B-8C20-40B7D2539E93 Q37625627-A7CBAC7B-FE9C-45FD-9FA4-261BA6F222A0 Q37712593-AA4CF6DE-C22D-4B63-8318-142C831064FC Q37739485-7B39DDD7-1D96-4985-8F61-08F7228CEB6E Q38101567-02852F5F-C285-4B92-99DD-E0CA9EF15310 Q38195120-D9427BFC-345C-43ED-A58A-CFEA945D4C44 Q38216836-A98E9E32-1611-4689-A29F-0B6D2427907E Q38542034-1A53D987-3141-4903-9274-39AEA9FE26A7 Q38599353-0C939CA5-DD66-48D2-A07B-1452926BB5C6 Q38666862-86341698-AC69-4AFA-B743-8CD77FC28840 Q38723957-2C7BEDC4-913B-486B-AE8E-D8A75C7FDFFC Q38772382-66C52377-6CBF-409A-8230-8D5F835AF02E Q38773351-B1C35CA3-5694-4D3C-B5C8-A6C87E3E1EA3 Q38819645-D6FC2796-5EDD-40E4-A555-243CD9FA1785 Q38849985-0E9A75C0-16EE-4ED9-B323-9346623051A2 Q38930242-3DA26B76-9A28-45AD-BD35-8AD8D162A409 Q38977425-E59F7AE5-9386-4D60-88C7-A06D78AFF226 Q39002036-2FD1650E-0DF5-4EA4-8A2B-5AC18C144087 Q39281940-9C8BF6B4-7EBD-47CA-AF02-2A44BA460F5F Q40038526-53DAD81D-3428-4735-ACDF-FAC7A6B121E7 Q40074629-71139BB6-1AD5-4FF3-8C7D-44A91CF2F57D Q42134875-A41922FF-0A97-46C9-B671-C7B46EB32CAA Q42221543-30AC0569-7444-41AC-A35C-622E98BBECE3

P2860

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

http://www.wikidata.org/entity/Q36460314

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Bispecific and trispecific kil ...... icity and cytokine production.

@ast

Bispecific and trispecific kil ...... icity and cytokine production.

@en

type

label

Bispecific and trispecific kil ...... icity and cytokine production.

@ast

Bispecific and trispecific kil ...... icity and cytokine production.

@en

prefLabel

Bispecific and trispecific kil ...... icity and cytokine production.

@ast

Bispecific and trispecific kil ...... icity and cytokine production.

@en

P1433

Q36460314-01400E70-0E0E-4F88-A066-D9B491BA267D

P1476

Q36460314-A5F314D5-5F5B-40FC-AB8C-B3F147442B7E

P2093

Q36460314-084CC393-15D0-4D41-8A91-8B18B6D290FC

Q36460314-18CD38E3-35CD-476E-883D-1B3C7D11AB73

Q36460314-7016A2D8-E58A-4D4D-BB7F-84669CD9CFA6

Q36460314-8FB1B4D0-A559-46D4-B7BC-A43A19B0E869

Q36460314-9115F904-796E-4FF3-9CA4-CBF5B91D87EC

Q36460314-ABD8A9B1-9F19-423C-9D74-ED3C9F837715

Q36460314-C50AD1D0-C97E-488E-8327-4DFEE545A2DC

Q36460314-FADB2077-9066-4CC4-962A-BF2BCD08D50A

P2860

Q36460314-0247F7F0-B962-42EB-ABF0-CA3BFC84ADA3

Q36460314-04FD3B6C-D973-4E8B-98F6-60C8A9786F9F

Q36460314-0A247750-1465-4220-8438-BFA9136E1864

Q36460314-0F53E068-6BA1-4635-B056-2C7A14B62797

Q36460314-193A17D4-4A4A-4CAA-A6BF-8F40C22056FF

Q36460314-25E8972D-3E54-41A5-9756-A3F26082B499

Q36460314-27348913-1B9F-450A-8DDF-A4AE30981524

Q36460314-2C2CC184-53F3-4EA9-8F78-89835980A526

Q36460314-2D5C3916-12A9-43FB-A107-28990C82E64A

Q36460314-2DBEEDE7-4ED2-4E4B-A8E7-1401A751BD99

P304

Q36460314-39D32604-9E9E-423A-85F2-083DCFCC4DD4

P31

Q36460314-CC1EA386-D6D6-4BE9-8F48-C892D7D934BB

P356

Q36460314-B1B2EEB7-711C-4BFD-B2FE-D70E9F1D70D3

P433

Q36460314-8C1E7F1B-0C88-4527-85BC-A0E9B4B3342D

P478

Q36460314-830E1548-6711-4FC6-8959-83ED2A79436F

P50

Q36460314-D4E4F80D-A119-4A12-A26E-394C16ECD2C7

Q36460314-F7DCCA65-902A-4DE5-B063-3F6516D95F38

P577

Q36460314-7CF42D7F-F376-42D6-88F4-529AC79724F0

P698

Q36460314-AE719165-FD2A-4E22-A2F5-43EC323ABC2D

P921

Q36460314-F9A2FE2A-005C-41E5-96B1-0BF35D51B96D

P932

Q36460314-FF64CC59-7A68-4401-94B8-C3BF7A1241BC

P356

1535-7163.MCT-12-0692

P1433

Molecular Cancer Therapeutics

P1476

Bispecific and trispecific kil ...... icity and cytokine production.

@en

P2093

Bin Zhang

http://www.w3.org/2001/XMLSchema#string

Daniel A Vallera

http://www.w3.org/2001/XMLSchema#string

Deborah A Todhunter

http://www.w3.org/2001/XMLSchema#string

Louis M Weiner

http://www.w3.org/2001/XMLSchema#string

Michael R Verneris

http://www.w3.org/2001/XMLSchema#string

Michelle K Gleason

http://www.w3.org/2001/XMLSchema#string

Sophia X Zhou

http://www.w3.org/2001/XMLSchema#string

Valarie McCullar

http://www.w3.org/2001/XMLSchema#string

P2860

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification

NK cell recognition

IgG Fc receptors

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Regulation of human NK-cell cytokine and chemokine production by target cell recognition.

Control of immunity by the TNFR-related molecule OX40 (CD134)

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes.

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification.

P304

2674-2684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-12-0692

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey S. Miller

Angela Panoskaltsis-Mortari

P577

2012-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23075808

http://www.w3.org/2001/XMLSchema#string

P921

P932

3519950

http://www.w3.org/2001/XMLSchema#string